22.74

4.17% 0.91

After Hours: 22.74

Arcutis Biotherapeutics Inc (ARQT)

Overview News Price History Option Chain Financials Why ARQT Down? Discussions Forecast

Arcutis Biotherapeutics Inc stock is traded at $22.74, with a volume of 808.30K. It is up +4.17% in the last 24 hours and down -15.81% over the past month. Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.

Previous Close:

$21.83

Open:

$22.03

24h Volume:

808.30K

Relative Volume:

0.55

Market Cap:

$2.82B

Revenue:

$376.07M

Net Income/Loss:

$-16.14M

P/E Ratio:

-162.54

EPS:

-0.1399

Net Cash Flow:

$-16.31M

1W Performance:

+2.25%

1M Performance:

-15.81%

6M Performance:

+35.92%

1Y Performance:

+32.90%

1-Day Range:

$21.95

$23.00

1-Week Range:

$21.57

$23.46

52-Week Range:

$11.86

$31.77

Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile

Name

Arcutis Biotherapeutics Inc

Sector

Healthcare (1114)

Industry

Biotechnology (623)

Phone

805-418-5006

Address

3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA

Employee

354

Twitter

@ArcutisBio

Next Earnings Date

2024-12-06

Latest SEC Filings

ARQT's Discussions on Twitter

Compare ARQT vs VRTX, REGN, ALNY, ARGX, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ARQT Arcutis Biotherapeutics Inc	22.74	2.71B	376.07M	-16.14M	-16.31M	-0.1399
VRTX Vertex Pharmaceuticals Inc	454.97	113.96B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	749.47	78.41B	14.34B	4.50B	3.77B	41.56
ALNY Alnylam Pharmaceuticals Inc	328.70	40.85B	3.71B	313.75M	465.38M	2.2571
ARGX Argen X Se Adr	697.05	42.05B	4.16B	1.29B	734.26M	19.58
INSM Insmed Inc	148.31	29.99B	606.42M	-1.28B	-997.58M	-6.403

Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-25-25	Initiated	Goldman	Neutral
Dec-30-24	Initiated	H.C. Wainwright	Buy
Aug-28-24	Initiated	Jefferies	Buy
Jan-03-24	Upgrade	Mizuho	Neutral → Buy
Oct-26-23	Downgrade	Mizuho	Buy → Neutral
Oct-13-23	Downgrade	Goldman	Buy → Neutral
Sep-07-22	Initiated	Needham	Buy
Mar-17-22	Initiated	Goldman	Buy
Jun-30-21	Initiated	Mizuho	Buy
May-27-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Nov-09-20	Upgrade	Goldman	Neutral → Buy
Oct-08-20	Initiated	Truist	Buy
Feb-25-20	Initiated	Cantor Fitzgerald	Overweight
Feb-25-20	Initiated	Cowen	Outperform
Feb-25-20	Initiated	Goldman	Neutral
Feb-25-20	Initiated	Guggenheim	Buy

View All

Arcutis Biotherapeutics Inc Stock (ARQT) Latest News

08:10 AM

Arcutis (ARQT) announces long-term phase 3 data for ZORYVE cream in children - MSN

08:10 AM

Mar 23, 2026

Understanding the Setup: (ARQT) and Scalable Risk - Stock Traders Daily

Mar 23, 2026

Arcutis Biotherapeutics (ARQT) Valuation Check After New Pediatric ZORYVE Phase 3 Extension Data - Yahoo Finance

Mar 23, 2026

Mar 18, 2026

Arcutis (ARQT) Announces Long-Term Phase 3 Data for ZORYVE Cream in Children - Insider Monkey

Mar 18, 2026

Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting - Bitget

Mar 18, 2026

Arcutis Biotherapeutics (ARQT) Unveils New Trial Data at Dermato - GuruFocus

Mar 18, 2026

New eczema treatment data in infants and kids set for 2026 AAD - Stock Titan

Mar 18, 2026

Mar 17, 2026

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Mar 17, 2026